Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty‐Two–Week Randomized, Double‐Blind, Placebo‐Controlled Study

OBJECTIVE: To assess the efficacy and safety of subcutaneous (SC) belimumab in patients with systemic lupus erythematosus (SLE). METHODS: Patients with moderate‐to‐severe SLE (score of ≥8 on the Safety of Estrogens in Lupus Erythematosus National Assessment [SELENA] version of the SLE Disease Activi...

Descripción completa

Detalles Bibliográficos
Autores principales: Stohl, William, Schwarting, Andreas, Okada, Masato, Scheinberg, Morton, Doria, Andrea, Hammer, Anne E., Kleoudis, Christi, Groark, James, Bass, Damon, Fox, Norma Lynn, Roth, David, Gordon, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Systemic Lupus Erythematosus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434872/
https://www.ncbi.nlm.nih.gov/pubmed/28118533
http://dx.doi.org/10.1002/art.40049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434872/
https://www.ncbi.nlm.nih.gov/pubmed/28118533
http://dx.doi.org/10.1002/art.40049

Ejemplares similares